

<b>(51) International Patent Classification 6 :</b> <b>A61L 33/00, 27/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/08551</b> <b>(43) International Publication Date:</b> 5 March 1998 (05.03.98)
<b>(21) International Application Number:</b> PCT/US96/13783 <b>(22) International Filing Date:</b> 29 August 1996 (29.08.96) <b>(71) Applicant:</b> MEDTRONIC, INC. [US/US]; 7000 Central Avenue Northeast, Minneapolis, MN 55432 (US). <b>(72) Inventors:</b> CAHALAN, Linda, L.; Elegastraat 10, NL-6166 KE Geleen (NL). CAHALAN, Patrick, T.; Elegastraat 10, NL-6166 KE Geleen (NL). VERHOEVEN, Michel; Parallelweg 39, NL-6221 BD Maastricht (NL). HENDRIKS, Marc; Raambouwstraat 118, NL-6432 RV Hoensbroek (NL). FOUACHE, Benedicte; Achter De Molens 7, NL-6211 JC Maastricht (NL). <b>(74) Agents:</b> LATHAM, Daniel, W. et al.; Medtronic, Inc., 7000 Central Avenue Northeast, MS301, Minneapolis, MN 55432 (US).		<b>(81) Designated States:</b> AU, CA, JP, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> BIOCOMPATIBLE MEDICAL ARTICLE AND METHOD  <b>(57) Abstract</b> <p>A medical article having a metal or glass surface with the surface having an adherent coating of improved biocompatibility. The coating is made by first applying to the surface a silane compound having a pendant vinyl functionality such that the silane adheres to the surface and then, in a separate step, forming a graft polymer on the surface with applied vinylsilane such that the pendant vinyl functionality of the vinylsilane is incorporated into the graft polymer by covalent bonding with the polymer. Biomolecules may then be covalently attached to the base layer.</p> <p style="text-align: right;"><b>BEST AVAILABLE COPY</b></p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

# BIOCOMPATIBLE MEDICAL ARTICLE AND METHOD

## BACKGROUND OF INVENTION

The present invention generally relates to medical devices for implantation in a human or animal body which are provided with improved tissue and blood biocompatibility.

5 More specifically, metal or glass portions of the medical device are provided with a surface which has been chemically modified with covalently attached bioactive molecules.

Medical devices which serve as substitute blood vessels, synthetic and intraocular lenses, electrodes, catheters and the like in and on the body or as extracorporeal devices intended to be connected to the body to assist in surgery or dialysis are well known.

10 However, the use of such biomaterials in medical devices can stimulate adverse body responses, including rapid thrombogenic action. Various plasma proteins play a role in initiating platelet and fibrin deposition on plastic surfaces. These actions lead to vascular constriction to hinder blood flow, and the inflammatory reaction that follows can lead to the loss of function of the medical device.

15 A "biomaterial" may be defined as a material that is substantially insoluble in body fluids and that is designed and constructed to be placed in or onto the body or to contact fluid of the body. Ideally, a biomaterial will not induce undesirable reactions in the body such as blood clotting, tissue death, tumor formation, allergic reaction, foreign body reaction (rejection) or inflammatory reaction; will have the physical properties such as  
20 strength, elasticity, permeability and flexibility required to function for the intended purpose; can be purified, fabricated and sterilized easily; will substantially maintain its physical properties and function during the time that it remains implanted in or in contact with the body.

As used herein, the solid surface of a biomaterial is characterized as  
25 "biocompatible" if it is capable of functioning or existing in contact with biological fluid and/or tissue of a living organism with a net beneficial effect on the living organism. Long term biocompatibility is desired for the purpose of reducing disturbance of the host organism. One approach to improved biocompatibility for biomaterials is to attach various "biomolecules" which can promote the attachment and growth of a normal cell or protein  
30 layer such that the body accepts the device as a normal part of the body. Biomolecules such as growth factors and cell attachment proteins which have been attached to the device

surface could be used for this purpose. In addition, biomolecules such as antithrombogenics, antiplatelets, anti-inflammatories and the like have also been used to improve the biocompatibility of surfaces.

5 A number of approaches have been suggested to attach such biomolecules. One such approach is set forth in Dekker et al., "Adhesion of endothelial cells and adsorption of serum proteins on gas plasma-treated polytetrafluoroethylene", *Biomaterials*, vol. 12 March 1991. In that approach, PTFE substrates were modified by radio frequency plasma to improve the wettability of the surface. Human serum albumin, human fibronectin, human immunoglobulin and human high-density lipoprotein were adsorbed to the plasma-treated  
10 substrates followed by seeding with human endothelial cells. Another approach is described in U.S. Patent 5,055,316 to Hoffman et al in which serum proteins such as albumin, immunoglobulins, fibrinogen or fibronectin, or proteins from different sources such as protein-A or glycoproteins are bound to a surface by first using plasma gas discharge in the presence of a plasma-polymerizable fluorinated hydrocarbon gas to provide  
15 a plasma-deposited surface, followed by exposure to a solution of the protein. Covalent attachment of such biomolecules can be found in Ito et al., "Materials for Enhancing Cell Adhesion by Immobilization of Cell-Adhesive Peptide", *Journal of Biomedical Materials Research*, 25:1325-1337 (1991) in which fibronectin or RGD peptide are bonded to the hydrogel by the use of a water soluble carbodiimide. Although this method allows coupling  
20 of the biomolecule extended from the surface, the fact that the biomolecule is immobilized throughout the gel layer reduces the availability of the biomolecule for interaction with, for example, cells intended to adhere to the biomolecule.

Spacer molecules have been used to address this problem. A spacer molecule is a molecule or compound which is capable of attachment to a solid surface, is large enough to  
25 extend from the surface of said surface and is capable of immobilizing a biomolecule and/or biomolecules. The spacer insures that the active site of the biomolecule is held outward away from the support so as to contact the body fluid efficiently. The spacers are derived from organic molecules having at least two reactive functional groups, or more, generally situated at opposing ends of the molecule. Such groups serve as attachment vehicles  
30 capable of coupling the spacer to the solid surface and to the biomolecule. For example, in U.S. Patent 5,132,108 to Narayanan et al., a copolymer surface was subjected to radio

frequency plasma treatment by subjecting it to a radio frequency electric field in the presence of a water vapor plasma medium. An aqueous solution of polyethyleneimine (PEI) and 1-(3-dimethylpropyl)-3-carbodiimide (EDC) coupling agent was applied to the radio frequency plasma discharge modified polyurethane surface. An aqueous solution of heparin and EDC was then applied to the PEI-treated surface in order to provide a polymeric surface having an anti-thrombogenic agent secured to its surface. However, considering the heterogeneity of the polyurethane surface even coating with the multi-functional spacer molecule is not guaranteed.

Additional coverage can be provided, for example, according to U.S. Patent 4,565,740 to Golander et al. or U.S. Patent 5,049,403 to Larm et al. In the first of these patents, a complex of a polymeric cationic surfactant (e.g. a polyalkyleneimine) and a dialdehyde (e.g. glutaraldehyde) is adsorbed onto a substrate material. In the second of these patents, a polyamine is adsorbed onto the surface of a substrate and crosslinked with crotonaldehyde. Multiple coatings, including intermediate layers of anionic material are then applied to obtain an effective coating. However, these crosslinked coatings rely on adsorption onto the surface and ionic bonding to the surface, which may not provide good bonding of the coating to the surface.

The inventors of the present invention have contributed to improvements in biocompatibility of biomaterials through the use of multilayer coatings in their U.S. Patents 5,229,172; 5,308,641 and 5,350,800. For example, in U.S. Patent 5,229,172, we discovered a method for modifying the surface characteristics of a polymeric material by providing a base layer of grafted acrylamide on the polymeric surface which can be used to attach various spacers and biomolecules. Or, in U.S. Patent 5,308,641, we discovered an improved spacer material which includes a polyalkyleneimine covalently attached to an aminated substrate and crosslinked with a crosslinking agent which is difunctional in aldehyde groups. Or, in U.S. Patent 5,350,800, we discovered a method for attaching a biomolecule having carboxyl groups to an aminated solid surface by a carbodiimide and then selectively restoring the bio-functionality of the carboxyl groups.

On metal or glass surfaces, the binding of the base layer of such multi-layer coatings can be a problem since there is no organic structure to provide covalent bonds between the metal or glass substrate and the grafted base layer. Others have addressed the problem of

binding to metals and glass by applying aminosilanes to adhere to the surface and then attaching the biomolecule to the aminosilane through the amine functionality of the aminosilane. This can be seen in U.S. Patent 5,355,433 issued to Rowland et al in which an aminosilane is used to adhere a heparin molecule to an oxidized tantalum surface.

5 Aminosilanes are also disclosed for attachment of a heparin molecule to glass or metal surfaces in U.S. Patent 4,118,485 issued to Eriksson et al. However, the use of aminosilanes in coatings of this sort has not been very good in producing a surface with a high level of both bioeffectiveness and stability.


10 It is therefore an object of the invention to provide a base for the attachment of biomolecules and/or spacer molecules with improved stability on metal or glass substrates.

It is also an object of the invention to provide a combined base/spacer which presents a stable platform for the attachment of the biomolecule and thereby prevents the attached biomolecule from being buried in the spacer layer.

#### Summary of the Invention

15 The present invention therefore includes a medical article having a metal or glass surface with the surface having an adherent coating. The coating includes a silane compound having a vinyl functionality such that the silane adheres to the surface with the vinyl functionality pendant from the surface and then forming a graft polymer on the surface with applied silane such that the pendant vinyl functionality of the silane is incorporated into the graft polymer by covalently bonding it to the graft polymer.

20 The preferred silane is generally a compound of the structure



where X is a halogen, methoxy or ethoxy groups. Compounds of this type include the preferred compound trichlorovinylsilane. Other silanes can also be used as set forth in greater detail below.

25 The base layer which incorporates the vinyl functionality of the silane also includes a thin but densely formed graft polymer. Preferably, the graft polymer is formed by free radical reaction from an ethylenically unsaturated monomer. Thus the reaction which forms the graft polymer also activates the pendant vinyl group of the silane and incorporates it into the graft polymer during its formation. An oxidizing metal such as ceric ion can be used to initiate the polymerization reaction. Ceric ion grafting is known to work best when

30

the monomer does not have a tendency to precipitate with the ceric ion, for instance, when used with acrylamide. Acrylic acid is also a good candidate monomer for use with ceric ion grafting provided that polymerization inhibitors present in commercial supplies of acrylic acid are first removed by distillation. Blends of acrylic acid, acrylamide and other monomers can also be used depending on the desired properties of the graft.

The biofunctional molecules attached to grafted surfaces can be biomolecules such as anticoagulants (e.g. heparin, heparin sulfate, dermatan sulfate, glycosaminoglycan sequences and analogs, hirudin, thrombin inhibitors), thrombolytic agents (e.g. streptokinase, tissue plasminogen activator), procoagulant agents, platelet adhesion inhibitors, platelet activity inhibitors, cell attachment proteins, growth factors/cytokines, wound healing agents, antimicrobial agents, anticancer agents, hormones, analgesics, detoxification agents and the like. These biomolecules can be covalently bonded to the grafted surface by pendant functional groups such as amine and carboxyl groups in the grafted polymer which are reacted with corresponding groups on the biofunctional molecules according to methods which are well known by those skilled in the art.


Preferably, a medical article according to the present invention includes a spacer as a means for attachment for the biomolecule. Such spacers are well known in the art as set forth above in the background of the invention. A preferred spacer can be a polyamine spacer as set forth in our U.S. Patent 5,308,641 which is hereby incorporated by reference in its entirety.

Examples of devices which may be provided with biocompatible surfaces in accordance with this invention include prosthetic devices and components of implanted prosthetic devices such as in vascular grafts or hard tissue prosthetics, invasive devices such as indwelling catheters or in devices for extracorporeal blood handling such as dialysis equipment or blood circulation or oxygenation equipment used in cardiovascular surgery. In a particular vascular prosthesis embodiment of the invention, the base layer described above can be attached to a metallic medical device which undergoes movement during implantation and/or use, since the bioactive coating is able to withstand flexure without cracking or delamination. Exemplary in this regard are metallic radially expandable generally tubularly shaped endoprostheses which are generally known as stents. An exemplary stent in this regard is described in U.S. Patents 4,886,062 and 5,133,732 issued


to Wiktor, the subject matter thereof being incorporated by reference. Stents such as these are made of very fine gauge metallic wire, typically tantalum wire or stainless steel wire. During implantation, these stents are mounted onto the balloon of an angioplasty catheter or the like until a partially occluded location along a blood vessel or the like is reached, at which time the balloon and the stent are radially and circumferentially expanded for purposes of opening the occlusion and supporting the vessel at that location. This necessarily involves rather extensive bending of the tantalum wire. Many coatings do not have the flexibility and/or adherence properties which are needed to avoid cracking and/or loss of the coating when subjected to this type of flexure. Further, a stent provided with heparin as a biomolecule according to the present invention and implanted within a blood vessel can prevent thrombus formation on the metallic member that may otherwise occur as a result of the stent implantation procedure.

#### Detailed Description of the Invention

The base layer of the multilayer coating is made by first applying to the surface a silane having a pendant vinyl functionality such that the silane adheres to the surface. The silane used includes compounds of the structure



or, optionally



where X is a halogen, methoxy or ethoxy group, and R is a short chain alkyl group. A preferred silane compound is trichlorovinylsilane.

Those skilled in the art will recognize that the successful application of the silane to a surface includes precleaning of the surface and the control of moisture at the surface during application of the silane. Multistep cleaning and drying operations are therefore used to provide a clean surface and to control moisture. An exemplary method for cleaning and drying can be found herein in the examples.

The base layer which incorporates the vinyl functionality of the silane includes a thin but densely formed graft polymer. Preferably, the graft polymer is formed by free radical reaction from an ethylenically unsaturated monomer. Thus the reaction which forms the graft polymer also activates the pendant vinyl group of the silane and incorporates it into



the graft polymer during its formation. An oxidizing metal such as ceric ion can be used to initiate the polymerization reaction.

The preferred grafting process is carried out on the substrate in an aqueous solution (20 to 40 wt% of monomer) as contrasted with other solvent polymerization processes such as organic solvent polymerization or even bulk polymerization. The composition of the preferred monomer solution is predominantly acrylic acid and acrylamide in order to provide a desired density of carboxyl groups on the grafted surface which can be used to attach the biomolecule or a spacer layer. Alternatively, acrylamide can be used exclusively followed by hydrolysis treatment on the resulting polymer to provide the desired density of carboxyl groups.

The grafting reaction of the present invention may be carried out at temperatures between about 18°C and 25°C. The present invention may be carried out under pressure or under partial vacuum, but it is preferred to utilize atmospheric pressure inasmuch as the reaction proceeds very favorably at this pressure. The pH of a grafting solution with ceric ammonium nitrate is typically about 1.4.

The amount of ceric ion utilized in the practice of the process of the present invention can be varied over fairly wide limits. For example, one may utilize from about 0.0001 to 0.002 mole of ceric ion per mole of polymerizable monomer. Preferably one would use between 0.0002 to 0.0005 mole of ceric ion per mole of acrylamide. Ceric ion is preferably introduced into the reaction mixture in the form of a ceric salt. Among the cerium salts adapted for use in the present invention are ceric nitrate, ceric sulfate, ceric ammonium nitrate, ceric ammonium sulfate, ceric ammonium pyrophosphate, ceric iodate, ceric salts of organic acids, such as cerium naphthenate and cerium linoleate and the like. These compounds may be employed singly or in combination with one another.

In general, the time required to achieve a desired degree of polymerization may be determined empirically. Thus, for example, acrylamide may be grafted at different time intervals and the extent of grafting determined by staining of functional groups introduced in the graft by chemical modification. The length of the polymeric chain and graft density may be varied by varying the acrylamide concentration, ceric ion concentration, temperature and oxygen concentration.

Biofunctional molecules (biomolecules) such as anticoagulants (e.g. heparin, heparin sulfate, dermatan sulfate, glycosaminoglycan sequences and analogs, hirudin, thrombin inhibitors), thrombolytic agents (e.g. streptokinase, tissue plasminogen activator), procoagulant agents (e.g. Factor VIII, von Willebrand's Factor, collagen), platelet adhesion inhibitors (e.g. albumin, albumin adsorbing surfaces, hydrophilic hydrogels, phospholipids), platelet activity inhibitors (e.g. aspirin, dipyrimadole, forskolin), cell attachment proteins (fibronectin, vitronectin, different collagen types, laminin, elastin, basement membrane proteins, fibrin, peptide sequences), growth factors/cytokines (e.g. transforming growth factor, basic fibroblast growth factor, platelet derived growth factor, endothelial cell growth factor, gamma interferon), hydrogels, collagens, epidermal growth factor, antimicrobial agents (e.g. gentamicin, rifampin, silver salts), anticancer agents (e.g. 5-fluorouracil), hormones (insulin, vasopressin progesterone, human growth hormone), analgesics, detoxification agents (e.g. chelating agents) and the like can be ionically or covalently bonded to a metallic substrate by first applying the grafting method of the present invention to provide a suitable surface to which to attach the biomolecule. Such molecules can be covalently attached to a grafted surface made according to the present invention in which pendant functional groups such as amine and carboxyl groups introduced in the gel by chemical modification are reacted with corresponding groups on the biofunctional molecules according to methods which are well known by those skilled in the art.

Preferably, a medical article according to the present invention includes a spacer molecule as a means for attachment for the biomolecule. Such spacer molecules are well known in the art as set forth above in the background of the invention.

The preferred spacer molecule is a polyalkyleneimine or other branched polyamines. By polyalkyleneimine we therefore mean to include the water soluble, hydrophilic, polyamines evolving from aziridine and azetidine monomers such as 1-unsubstituted imines, 1-substituted basic imines, activated imines (1-acyl substituted imines), isomeric oxazolines/oxazines and the like. The polyalkyleneimines employed in the present invention are preferably highly branched, thereby possessing primary, secondary, and tertiary amine groups. Thus, ethyleneimine polymerized by classical cationic chain-growth polymerization, either alone or with other monomers suitable for copolymerization with ethyleneimine, could be used in the present invention.

A crosslinking agent can be employed in the present invention in order to provide additional stability of the polyamine spacer. The crosslinking agent can be any crosslinking agent which is at least difunctional in groups which are reactive with the amine groups present in the polyamine spacer. The crosslinking agent may therefore have an aldehyde functionality. For example, glutaraldehyde, crotonaldehyde, goxal, maonaldehyde, succinaldehyde, adipaldehyde, and dialdehyde starch could be used. Other suitable crosslinking agents are cyanuric chloride and derivatives, divinyl sulfone, epoxy compounds, imidate esters and other crosslinking agents reactive toward amines.

The spacer of the present invention can therefore be made by applying a polyalkyleneimine to the grafted surface and then treating the applied polyalkyleneimine with the crosslinking agent. Preferably, the crosslinking agent used to crosslink the polyalkyleneimine is applied in dilute solution and at a suitable pH to accomplish light crosslinking. For example, an aldehyde solution that has a concentration in the range of about 0.0005 M to about 0.05 M could be used while a concentration in the range of about 0.0005 M to about 0.005 M would be preferred. Also, for example, a pH for the aldehyde solution in the range of about 7 to about 10 would be preferred. The time required to complete the light crosslinking reaction is typically just a few minutes in the case of dialdehydes or longer times for other crosslinkers. Preferably, the crosslinking reaction with the polyamine is undertaken before applying it to the grafted surface.

The polyalkyleneimine is covalently bonded to the grafted surface by contacting the grafted surface with an activating agent which will activate the carboxyl groups on the grafted surface and cause them to bind to the polyalkyleneimine. The covalent bonding agent used is preferably a water soluble carbodiimide of the structure  $R_1N=C=NR_2$  where  $R_1$  can be an alkyl or cycloalkyl group and  $R_2$  can be an alkylamine or cycloalkylamine group such as 1-ethyl-3-(3-dimethyl-aminopropyl) carbodiimide hydrochloride, or 1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide. The reaction with the carbodiimide is undertaken in a cold solution (0-4°C) at a pH of about 5 although a room temperature reaction is also acceptable. The grafted surface can be pretreated with the carbodiimide and then contacted with the polyamine or, preferably, the grafted surface can be coated with the polyamine and then treated with the carbodiimide. Preferably, the polyamine and carbodiimide are previously mixed together at a pH of approximately 9 before applying to

the graft. In the reaction, the carbodiimide activates the carboxyl groups of the graft after reaction with the polyamine which leads to the formation of a suitable amide bond, resulting in effective immobilization of the polyamine on the grafted surface.

5 The immobilized polyamine can then be used as a platform for the immobilization of various biofunctional molecules. For example, in the case of heparin, the heparin can be modified to contain a reactive aldehyde moiety which does not inhibit the bioactivity of the heparin but does react with the amine groups of the polyamine to covalently attach the heparin to the polyamine in the presence of a suitable reducing agent such as  $\text{NaCNBH}_3$ . The aldehyde groups can be formed on heparin by controlled periodate oxidation. Part of 10 the saccharide molecules in the heparin contain unsubstituted glycol structures (c(2)-OH AND C(3)-OH), which react with periodate splitting the C(2)-C(3) bond, generating a dialdehyde structure and leaving the polysaccharide main chain intact. After oxidation (under the exclusion of light) the solution containing the activated heparin can be diluted into a proper buffer to a suitable concentration. The solution is then applied to the 15 polyamine immobilized on the surface. The aldehyde functional groups on the heparin are then reacted with the free amine groups to give a Schiff base formation that may be reduced to provide stable secondary amines. Exemplary reducing agents include sodium borohydride, sodium cyanoborohydride, dimethylamine borane and tetrahydrofuran-borane. Upon completion of the coupling reaction, the surface may be washed with water and 20 solutions of sodium chloride to remove loosely bound or unreacted heparin.

#### Example 1

25 A piece of coiled tantalum wire was ultrasonically cleaned in 2% Micro-clean for 30 minutes followed by ultrasonic treatment in deionized water for 30 minutes. This last step was repeated after which the coil was rinsed in isopropanol and dried at 50°C for 20 minutes.

The cleaned coil was swirled in a 2% solution of trichlorovinylsilane (Merck Darmstadt, FRG) in xylene for 60 seconds followed by rinsing for 60 seconds in xylene, 60 seconds in isopropanol, 60 seconds in water and finally in acetone. The coil was then allowed to air dry overnight.

30 The dried coil was then placed into a glass tube which was filled with 15 ml of an aqueous solution of 35 wt% of freshly distilled acrylic acid and 5 wt % acrylamide. To the

15 ml of monomer solution, 0.9 ml of a solution of ceric ammonium nitrate (0.1M) in nitric acid (0.1M) was added. Deaeration was performed for 3-5 minutes at about 18 mm Hg followed by ultrasonic treatment for 10 minutes and an additional incubation of 35-40 minutes, all at room temperature. The grafted samples were then rinsed 10 times with deionized water at 50°C followed by an overnight incubation at 50°C. Samples taken showed a deep stain when soaked in toluidine blue solution.

A solution of 375 ml crotonaldehyde in 0.1M sodium borate (pH=9.1) was made and after 10 minutes stirring polyethyleneimine (PEI, Polymin SN from BASF with a  $M_w$  of 60,000) was added. After an additional mixing of 5 minutes, the coil was incubated in the crosslinked PEI solution for one hour while shaking. After rinsing with deionized water, the coil was contacted with a solution of 0.5 wt% PEI (Polymin SN) in 0.1M sodium borate (pH=9.1) for 10 minutes. Water soluble carbodiimide (1-(3-diethylaminopropyl)-3-ethylcarbodiimide.HCl) at a concentration of 0.05M was added. Coupling was allowed to proceed for one hour while shaking followed by rinsing with deionized water for 10 minutes.

Oxidized heparin was prepared by adding 0.165 mg  $\text{NaIO}_4$ /ml to 5 mg native heparin (Akzo)/ml 0.05M phosphate buffer (pH=6.88; 0.025M  $\text{K}_2\text{HPO}_4$  +  $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$ ) under the exclusion of light. After overnight oxidation, the resulting heparin solution was diluted in 0.4M acetate pH=4.6 at a ratio of 1:20. 0.1 mg of  $\text{NaCNBH}_3$  /ml was added to the diluted heparin and the coil was incubated in this solution for 2 hours at 50°C. After rinsing with deionized water, 1M NaCl and water again to remove loosely bonded heparin, the coil was incubated with toluidine blue which provided an even lilac stain, indicating successful heparinization. An additional bioactivity test was also successfully performed to determine the ability of the heparinized surface to deactivate thrombin via activation of previously adsorbed antithrombin III. The bioactivity was also tested successfully after an overnight challenge with 1% sodium dodecylsulfate at 50°C indicating excellent stability of the coating on the metal substrate.

#### Comparative Examples 2-8

Comparative tests were conducted on a variety of variables. Different methods to aminate the metal surface and their ability to bind heparin via the reductive amination process described in Example 1 were evaluated. Variables tested included the use of no

silane, an aminosilane, aminopropyl triethoxysilane (APTES), and a vinylsilane, trichlorovinylsilane (TCVS); the use of grafted polymers (acrylamide (AAm) and acrylic acid (Ac)) and copolymers as a base layer; adsorbed or grafted PEI layer; and various crosslinkings of the PEI layer (crotonaldehyde (Ca), glutaraldehyde (Gda) and divinylsulfone (DVS)). For Example 8, coils were prepared with a grafted hydrogel essentially as described in Example 1. A solution of 0.1 wt% PEI (Polymin SN from Basf with a  $M_w$  of 60,000) in 0.1M borate pH=9.0 was prepared to which water soluble carbodiimide (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.HCl, Aldrich) up to a concentration of 0.05M was added. Immediately after dissolution of the carbodiimide, the grafted coils were contacted with the solution for 50 minutes while gently shaking. After copious rinsing with water, heparin was coupled to the coils as described in Example 1. The test results for Examples 2-8 are given below in Table 1.

Table 1

Example	Silane	Process	PEI Layer	Bioactivity	Staining
2	None	Adsorbed	Basf/Ca	0.0465	0
3	APTES	Adsorbed	Basf/Ca	0.0864	0
4	APTES	Adsorbed	Fluka/DVS	0.1512	0
5	APTES	Adsorbed	Fluka/Gda	0.0090	0
6	TCVS	Graft/Ac	Basf/Ca	0.2192	4
7	TCVS	Graft	Basf/Ca	0.330	4+
		Ac+AAm			
8	TCVS	Graft	Basf	0.323	4+
		Ac+AAm			

The comparative test results in Table 1 indicate that the bioactivity of the adsorbed PEI layer (in IU of DEA/cm<sup>2</sup>) was less than that for a covalently bonded layer as present in Examples 7 and 8. Further, the staining following the overnight challenge with 1% sodium dodecylsulfate (on a scale of 0=no stain to 5=dark stain) showed that the heparin layer was not effectively maintained on test samples with the aminosilane and adsorbed PEI whereas the heparin layer was retained on the covalently bonded PEI.

It will be appreciated by those skilled in the art that while the invention has been described above in connection with particular embodiments and examples, the invention is

not necessarily so limited and that numerous other embodiments, examples, uses, modifications and departures from the embodiments, examples and uses may be made without departing from the inventive concepts.

5

10

15

20

25

30

**We Claim:**

1. An endoprosthesis having a metal surface contacting body fluids, the metal surface having a coating thereon comprising:

(a) a silane which includes a vinyl functionality, the silane adherent to the metal surface such that the vinyl functionality is pendant from the surface; and

(b) a graft polymer on the silane adherent surface such that the pendant vinyl functionality of the silane is covalently bonded with the graft polymer.

2. The endoprosthesis of claim 1 also comprising:

(a) a polyamine spacer covalently attached to the graft polymer; and

(b) a biomolecule covalently attached to the spacer.

3. An endoprosthesis as in claim 1, in which the silane also includes a functional group selected from the group consisting of halogen, methoxy and ethoxy groups.

4. An endoprosthesis as in claim 3, in which the silane is trichlorovinylsilane.

5. An endoprosthesis as in claim 1, in which the graft polymer is formed by free radical reaction from an ethylenically unsaturated monomer.

6. An endoprosthesis as in claim 5, in which the monomer is selected from acrylamide and acrylic acid.


7. An endoprosthesis as in claim 2, in which the polyamine spacer is a polyalkyleneimine.

8. An endoprosthesis as in claim 2, in which the biomolecule is an antithrombotic.

9. An endoprosthesis as in claim 8, in which the antithrombotic is selected from the group consisting of heparin and heparin derivatives.

10. A medical device having metal or glass surface in contact with body fluids, the surface having a coating thereon comprising:

(a) a silane having the structure



where X is a halogen, methoxy or ethoxy and R is an optional short chain alkyl group; the silane adherent to the surface such that the vinyl functional group is pendant from the surface; and



(b) a graft polymer formed by free radical reaction from an ethylenically unsaturated monomer, the graft polymer formed on the silane adherent surface such that the pendant vinyl functionality of the silane is incorporated into the graft polymer.

11. A medical device as in claim 10 also comprising:

(a) a polyalkyleneimine spacer covalently attached to the graft polymer; and

(b) a biomolecule covalently attached to the spacer.

12. A medical device as in claim 10, in which the silane is trichlorovinylsilane.

13. A medical device as in claim 10, in which the monomer is selected from acrylamide and acrylic acid.

14. A medical device as in claim 11, in which the biomolecule is an antithrombotic.

15. A medical device as in claim 14, in which the antithrombotic is selected from the group consisting of heparin and heparin derivatives.

16. In a radially expandable stent comprising a hollow cylindrical shape made of a low-memory level metal such that the metal can controllably deform to effect radial expansion of the stent from a first diameter to a second, expanded diameter, the metal coated with a biologically compatible coating, the improvement wherein the coating includes:

(a) a silane adherent to the metal; and

(b) a graft polymer covalently attached to the silane such that the coating is retained on the wire as the stent is expanded.

17. A stent as in claim 16 wherein the silane has a pendant vinyl functionality which is incorporated into the graft polymer.


18. A stent as in claim 17 wherein the biocompatible coating also comprises a biomolecule covalently attached to the spacer.

19. A method of providing a medical article having a glass or metal surface with a biocompatible coating on the glass or metal surface comprising the steps of:

(a) applying to the surface a silane having a vinyl functionality such that the silane adheres to the surface;

(b) forming a graft polymer on the silane adherent surface such that the vinyl functionality of the silane is incorporated into the graft polymer.

20. A method as in claim 19 wherein the silane has the structure



where X is a halogen, methoxy or ethoxy and R is an optional short chain alkyl group.

5 21. A method as in claim 20, in which the silane is trichlorovinylsilane applied to the surface in dilute solution.

22. A method as in claim 19, in which the graft polymer is formed on the silane adherent surface by applying to the silane adherent surface an ethylenically unsaturated monomer in the presence of a free radical initiator.

10 23. A method as in claim 19 also comprising the step of covalently attaching a biomolecule to the graft polymer.

24. A method as in claim 23, in which the biomolecule is covalently attached by the steps of:

- (a) covalently attaching a spacer molecule to the graft polymer; and
- (b) covalently attaching the biomolecule to the spacer molecule.

15 25. A method of providing a medical article having a glass or metal surface with a bioactive heparin coating on the glass or metal surface comprising the steps of:

- (a) applying to the surface a silane having a vinyl functionality such that the silane adheres to the surface;
- (b) forming a graft polymer on the silane adherent surface such that the vinyl functionality of the silane is incorporated into the graft polymer.
- 20 (c) covalently attaching a polyamine spacer to the graft polymer;
- (d) treating heparin to form aldehyde functional groups on the heparin; and
- (e) covalently attaching the heparin to the polyamine spacer.

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61L33/00 61L27/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 275 838 A (MERRILL EDWARD W) 4 January 1994 see column 7, line 9 - line 12 see column 7, line 57 - line 68 ---	1,2,5-9, 17-19
Y	US 5 229 172 A (CAHALAN PATRICK T ET AL) 20 July 1993 cited in the application see column 3, line 29 - line 44 see column 4, line 14 - line 34 see claims ---	1,2,5-9, 17-19
A	BIOMATERIALS, vol. 15, no. 10, 1 August 1994, pages 725-736, XP000464803 IKADA Y: "SURFACE MODIFICATION OF POLYMERS FOR MEDICAL APPLICATIONS" --- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

29 April 1997

Date of mailing of the international search report

20-05-1997

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Cousins-Van Steen, G

# INTERNATIONAL SEARCH REPORT

International Application No  
PC, /US 96/13783

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 202 055 A (HEIDE HELMUT ET AL) 13 May 1980 see column 2, line 22 - line 53 ---	1-24
A	US 5 336 518 A (NARAYANAN PALLASSANA V ET AL) 9 August 1994 cited in the application -----	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5275838 A	04-01-94	US 5171264 A	15-12-92
		AU 4533893 A	04-01-94
		WO 9325247 A	23-12-93
		AT 105735 T	15-06-94
		CA 2074730 A	29-08-91
		DE 69102062 D	23-06-94
		DE 69102062 T	05-01-95
		EP 0516749 A	09-12-92
		ES 2056641 T	01-10-94
		WO 9112886 A	05-09-91
US 5229172 A	20-07-93	EP 0611792 A	24-08-94
		JP 6239943 A	30-08-94
US 4202055 A	13-05-80	DE 2620907 A	17-11-77
		CH 613112 A	14-09-79
		FR 2350827 A	09-12-77
		GB 1541793 A	07-03-79
		NL 7704660 A,B,	15-11-77
		SE 424810 B	16-08-82
		SE 7705418 A	13-11-77
US 5336518 A	09-08-94	NONE	

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**